肺癌相关肿瘤标记物的临床应用  

Clinical application about lung cancer related tumor markers

作　　者：胡云辉[1] 赵春樱[1] 王若峥[1] 

机构地区：[1]新疆医科大学附属肿瘤医院放疗科,乌鲁木齐830011

出　　处：《新疆医科大学学报》2013年第1期16-20,共5页Journal of Xinjiang Medical University

基　　金：新疆维吾尔自治区科技支疆项目(201291171)

摘　　要：目的探讨血清细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)和神经特异性烯醇化酶(NSE)在肺癌中的表达及临床应用。方法选取411例肺癌患者,并分别根据病理分型分为鳞癌组、腺癌组、小细胞癌组;根据临床分期将非小细胞肺癌分为Ⅰ/Ⅱ期组、Ⅲ期组、Ⅳ期组,将小细胞肺癌分为局限期组、广泛期组;根据治疗效果分为CR+PR组、SD组、PD组。另选取健康体检者201例作为对照组进行比较,并检测受试者的CY-FRA21-1、CEA和NSE浓度。结果鳞癌组CYFRA21-1浓度为(9.15±1.83)ng/mL,高于其他组;腺癌组CEA浓度为(61.79±25.34)ng/mL,高于其他组;小细胞癌组NSE浓度为(39.45±5.20)ng/mL,高于其他组。Ⅳ期组NSCLC的CYFRA21-1、CEA和NSE浓度分别为(8.30±1.76)ng/mL、(59.32±28.30)ng/mL、(30.92±8.10)ng/mL,且均明显高于Ⅰ/Ⅱ期组与Ⅲ期组。广泛期组SCLC的CYFRA21-1、CEA和NSE浓度分别为(8.16±2.03)ng/mL、(34.18±21.75)ng/mL、(44.13±2.59)ng/mL,且均明显高于局限期组。CR+PR组治疗后CY-FRA21-1、CEA和NSE浓度明显低于治疗前,PD组治疗后CYFRA21-1、CEA和NSE浓度明显高于治疗前,差异均有统计学意义(P<0.05)。结论 CYFRA21-1、CEA和NSE可用于辅助预测肺癌的病理类型、临床分期及评价疗效。Objective To explore the expression of cytokeratin 19 fragment （CYFRA21-1）, carcinoembry onic antigen （CEA） and neuron specific enolase （NSE） in lung cancer and clinical application. Methods Four hundred and eleven patients with lung cancer were divided into squamous carcinoma group, adenocar cinoma group, small-cell cancer group according to pathology type and clinical stage, they were divided in to I/IIstage group, III stage group, IV stage group; they were divided into CR± PR group, SD group, PD group according to therapeutic efficacy. 201 healthy people as control group, and tested the level of CYFRA21-1, CEA and NSE. Results The levels of CYFRA21-1 in squamous cell carcinoma group was （9. 15±1.83） ng/mL, which was higher than other groups, the levels of CEA in adenocarcinoma group was （61.79±25.34） ng/mL which was higher than other groups, the levels of NSE in small cell carcinoma group was （39.45±5.20） ng/mL, which was higher than other groups. The levels of CYFRA21-1, CEA, NSEin IV stage group were （8.30±1.76） ng/mL, （59.32±28.30） ng/mL, （30.92±8. 10） ng/mL re spectively ,and which were higher than I / II stage group and III stage group in non small-cell lung cancer （NSCLC）. The levels of CYFRA21-1,CEA,NSE in extensive stage group were （8. 16±2.03） ng/mL, （34.18±21.75） ng/mL, （44.13!2.59） ng/mL, respectively,higher than limited stage group in small-cell lung cancer （SCLC）. Compared with before therapy and after therapy, the levels of CYFRA21-1, CEA, NSE in CR＋PR group were lower after therapy, but the levels of CYFRA21-1, CEA, NSE in PD group were higher after therapy. Conclusion CYFRA21-1, CEA, NSE maybe could assist to predict the pathology type, clinical stage and therapeutic efficacy for lung cancer.

关 键 词：肺癌 CYFRA21-1 CEA NSE 

分 类 号：R734.2[医药卫生—肿瘤]